相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2019)
Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
Ariella B. Hanker et al.
CANCER DISCOVERY (2019)
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER -positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.
Robert Hugh Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Neil Vasan et al.
SCIENCE (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress
Afsane Bahrami et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
Sarika Jain et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo et al.
LANCET ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer
Priyanka Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
B. Pistilli et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
Mathilde Guerin et al.
EUROPEAN JOURNAL OF CANCER (2017)
AKT Inhibition in Solid Tumors With AKT1 Mutations
David M. Hyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Jose Baselga et al.
LANCET ONCOLOGY (2017)
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung-Bae Kim et al.
LANCET ONCOLOGY (2017)
Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A new Light in the Darkness
Jordi Rodon et al.
CANCER DISCOVERY (2017)
Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)
C. Saura et al.
ANNALS OF ONCOLOGY (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
P. Vuylsteke et al.
ANNALS OF ONCOLOGY (2016)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
Maria Teresa Herrera-Abreu et al.
CANCER RESEARCH (2016)
Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors
Eneda Toska et al.
CLINICAL CANCER RESEARCH (2016)
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2016)
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Jose Baselga et al.
CLINICAL CANCER RESEARCH (2016)
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
Patricia Mucci LoRusso
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2016)
Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt
Jinfang Zhang et al.
MOLECULAR CELL (2016)
Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
Sharon T. Wilks
BREAST (2015)
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
Ana Bosch et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
Sara Tolaney et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Breast Cancer: Epidemiology and Etiology
ZiQi Tao et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2015)
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Lauren M. Thorpe et al.
NATURE REVIEWS CANCER (2015)
Molecular subtyping for clinically defined breast cancer subgroups
Xi Zhao et al.
BREAST CANCER RESEARCH (2015)
Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial.
Debu Tripathy et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
Cristina Saura et al.
CLINICAL CANCER RESEARCH (2014)
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
A. M. Gonzalez-Angulo et al.
CANCER TREATMENT REVIEWS (2013)
The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
Matthew J. Ellis et al.
CANCER DISCOVERY (2013)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer
Todd W. Miller et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis
Nathalie Dourdin et al.
CANCER RESEARCH (2008)
The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation
Jean J. Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells
JJ Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
LH Saal et al.
CANCER RESEARCH (2005)
Activation of the PI3K/Akt pathway and chemotherapeutic resistance
KA West et al.
DRUG RESISTANCE UPDATES (2002)
分享论文
